

PRALUENT® (alirocumab) Injection: Achieving Further LDL-C Control With Two Different Doses

Guest Speaker

Adina Gutstein
Cardiovascular Medical Associates, P.C.
Philadelphia, PA

Wednesday, November 16, 2016

Program Time: 6:30 PM - 9:30 PM

Program Registration Time: 6:00 PM

Morton's The Steakhouse

1411 Walnut Street
Philadelphia, PA 19102

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, this Program is limited to healthcare professionals and persons with bona fide professional interest in the information presented. Therefore, attendance at this Program by guests or spouses is not permitted. Please note that the value of any meal provided in connection with the Program may be reported in accordance with federal and state laws and regulations. If you currently hold a license in either Minnesota or Vermont or are an employee of the Veterans Administration, please note that we are not able to accommodate you at the presentation.

REGISTRATION FORM		
First Name:	M.I.	Last Name:
Degree(s): MD ☐ DO ☐ NP ☐ OD ☐ PA ☐ RN ☐ PhD ☐ RPh ☐ PharmD ☐	Credential Type (for Prescribers): ☐ Cardiovascular Specialist ☐ Primary Care ☐ Resident ☐ Fellow ☐ Other: _____	
Licensure State:	State License #:	Job Title:
Business Name:		Business Address:
Business Phone:		Business E-mail:
Location Type: Clinic ☐ or Hospital: Academic ☐ Community ☐ Other: ☐ If other, please specify:		
Have you previously attended a Regeneron Educational Program? Yes ☐ No ☐		

Please send your completed registration form to Brittany Hickcox with Regeneron Educational Programs at bhickcox@sphase.com or by fax to (678) 831-2741.

Questions regarding this Program should be directed to Brittany Hickcox at (770) 984-5174 or your Regeneron Medical Specialist, Matt Kozej, at (856) 281-8200 or matthew.kozej@regeneron.com.

This Program is being conducted by Regeneron Pharmaceuticals, Inc. No CME credits are available.

IMPORTANT SAFETY INFORMATION

PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization.

Please see accompanying full Prescribing Information.



SANOFI
Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807

REGENERON
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591

October 2015

US.ALI.15.10.021

PRB-0162

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

PRALUENT (alirocumab) is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C.

The effect of PRALUENT on cardiovascular morbidity and mortality has not been determined.

IMPORTANT SAFETY INFORMATION

PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization.

Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve.

The most commonly occurring adverse reactions ($\geq 5\%$ of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza.

Local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo.

Neurocognitive events were reported in 0.8% of patients treated with PRALUENT and 0.7% of patients treated with placebo. Confusion or memory impairment were reported more frequently by those treated with PRALUENT (0.2% for each) than in those treated with placebo ($<0.1\%$ for each).

Liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo.

The most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus $<0.1\%$).

PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT.

Please see accompanying full Prescribing Information


Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

SANOFI 

Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807

REGENERON

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591

October 2015 US.ALI.15.10.021 PRB-0162